Abstract
Forecasting SARS-CoV-2 epidemic trends with confidence more than a few weeks ahead is almost impossible as these entirely depend on political decisions. We address this problem by investigating the consequences for the health system of an epidemic wave of a given size. This approach yields semi-quantitative results that depend on the proportion of the population already infected and vaccinated. We introduce the COVimpact software, which allows users to visualise estimated numbers of ICU admissions, deaths, and infections stratified by age class at the French departmental, regional, or national level caused by the wave. We illustrate the usefulness of our approach by showing that for France, even with a 95% vaccination coverage, the current vaccine efficiency against the delta variant would make a large epidemic wave infecting 25% of the population difficult to sustain for the current hospital bed occupancy capacity. Overall, using the final epidemic wave size and ignoring detailed epidemiological dynamics yields valuable and practical insights to optimise public health response to epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the PhyEpi grant from the Occitanie Region and the ANR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: corentin.boennec{at}ird.fr
E-mail: samuel.alizon{at}cnrs.fr
E-mail: mircea.sofonea{at}umontpellier.fr
Data Availability
The data used in the study is publically available and the scripts used will be posted on a GitLab server.
